Skip to content

It looks like we may have content for your preferred language. Would you like to view this page in English?

Potential Pfizer- Allergan Deal Reignites Inversion Scrutiny

Loeb & Loeb partner John Settineri is quoted in a recent Law360 article regarding tax inversions. Pharmaceutical giant Pfizer’s potential cross-border deal with Irish drugmaker Allergan PLC has reignited the discussion of inversions roughly a year after rules surrounding the tax-motivated deal structure was tightened.  According to John, “The rules took aim at loopholes like the so-called hopscotch loans, used to access offshore cash while avoiding U.S. taxes, but they did not touch on a practice known as earnings stripping.”

Click here to read the article on the Law360 website.